Loading
Life sciences · Journal article
The Egyptian Journal of Internal Medicine · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Metabolically-dysfunction-associated steatotic liver disease (MASLD), the leading chronic liver condition worldwide, is driven by hyperinsulinemia and insulin resistance, with C-peptide serving as a stable marker of endogenous insulin secretion. In this perspective, we propose to redefine C-peptide as an active driver rather than a passive marker in MASLD pathogenesis. In our July 2025 cross-sectional study of 118 participants, we demonstrated that elevated serum C-peptide independently signals fibrosis risk in obese patients with MASLD, showing moderate correlation with the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score, acceptable discriminatory performance (AUC 0.75 at cut-off 1.78 ng/mL), and a linear relationship in regression modelling. Subsequent studies from late 2025 to early 2026 have advanced this foundation. Refined indices, such as the fasting C-peptide/HDL-C ratio (FHR) and HOMA2 IR-CP, exhibit nonlinear associations and superior predictive accuracy for MASLD in type 2 diabetes. Recently, C-peptide has been identified as a primary causal driver of hepatic steatosis, independent of peripheral resistance. We propose that C-peptide has evolved from a fibrosis biomarker to a mechanistic node and actionable target. Routine integration into metabolic screening could enhance early risk stratification and monitoring of therapies modulating hyperinsulinemia. The relatively small sample size of our cross-sectional cohort need more studies on larger scale. C-peptide deserves further study as a possible biomarker in future prospective trials validating its role in MASLD pathophysiology.